Oncology Frontier News

Kezdőlap
Magyarország
Budapest
Oncology Frontier News

Oncology Frontier is a leading medical media in the field of oncology in China with more than 50,0

Oncology Frontier is a leading medical media in the field of oncology in China with more than 50,000 readers. We are the first Chinese medical media to do onsite meeting report panoramically all over the World.

30/11/2023

At this 2023 ESMO, we were very glad to interview Dr. Nicolas Girard from Curie-Montsouris Chest Center. He analyzes the clinical implications of the bispecific EGFR/MET monoclonal antibody is expected to become the standard of care for advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 20 insertion mutation’s findings.
🔗Read more:

Editor's note: Based on the results of the PAPILLON trial, released at the ESMO 2023 Congress Presidential Symposium 1. The bispecific EG...

30/11/2023

At this 2023 ESMO, We were very glad to interview Dr. Antonio Passaro from the European Institute of Oncology in Milan, Italy. He shared with us the reviews of the exploration of the Amivantamab combination regimen in the treatment of EGFR-mutated NSCLC.
🔗Read more:

Editor's note: The ESMO 2023 released the internationally focused MARIPOSA, MARIPOSA-2 studies (Abstract LBA14 & LBA15), presenting result...

30/11/2023

At this 2023 ESMO, We were very glad to interview Dr. Domenica Lorusso from the Catholic University of the Sacred Heart in Milan, Italy. She shared with us the reviews of the comments on the results of the DUO-E and KEYNOTE-A18 trials.
🔗Read more:

Editor's note: The 2023 ESMO released several research advances in the field of gynecologic oncology, and Oncology Frontier invited Dome...

30/11/2023

At this 2023 ESMO, We were very glad to interview Dr. Jonathan Spicer from McGill University Health Centre. He shared with us insights on controversial issues in perioperative immunotherapy.
🔗Read more:

Editor's note: For operable EGFR/ALK-negative non-small cell lung cancer (NSCLC), the administration of immunotherapy has gradually become t...

30/11/2023

At the 2023 ESMO, we invited Dr. McCormack, from University College Hospital to share insights on the clinical implications of the INTERLACE study and hot topics in gynecologic oncology.
🔗Read more:

Editor's note: Mary McCormack, University College London Hospital, who reported data from the INTERLACE trial at the 2023 ESMO Annual Meet...

30/11/2023

At the 2023 ESMO, we invited Dr. Jarushka Naidoo, from the Beaumont RCSI Cancer Center, Ireland, to discuss how immunotherapy can help improve the quality of care for NSCLC.
🔗Read more:

Editor's note: Immunotherapy for operable EGFR/ALK-negative non-small cell lung cancer (NSCLC) has gradually become the new standard of ca...

10/10/2023

At this 2023 WCLC, We were very glad to interview Dr. David Harpole from Duke University, He shared with us his analyze the clinical implications of Surgical outcomes from AEGEAN Trial.
🔗Read more:

Editor's note: The 2023 WCLC has released the results of Surgical outcomes from AEGEAN Trial (Abstract OA12.05) and data of The EGFR-mutated...

10/10/2023

At this 2023 WCLC, We were very glad to interview Dr. Alex Drilon from Memorial Sloan Kettering Cancer Center. He shared with us the most concerned research and his views on the Advances in MET Target therapy released in 2023 WCLC.
🔗Read more:

Editor's note: The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (I...

09/10/2023

At this 2023 WCLC, We were very glad to interview the 2023 Distinguished Service Award Winner Dr. Ramalingam from Winship Cancer Institute of Emory University, to share with his acceptance speech for this award.
🔗Read more:

Editor's note: During the Opening Plenary Session of the 2023 World Conference on Lung Cancer, four leaders in the field of thoracic onco...

09/10/2023

At this 2023 WCLC in Singapore, We were very glad to interview Dr. Reguart, from the Hospital Clinic Barcelona, Spain.
She shared her views on small cell lung cancer immunotherapy data and clinical concerns.
🔗Read more:

Editor's note: At this 2023 WCLC, the first Oral Presentation Session (OA01: Advancing Immunotherapy in ES-SCLC), which released the resul...

09/10/2023

At this 2023 WCLC, The Oncology Frontier team traveled to Singapore to get a direct look at the WCLC. Fiona Hegi-Johnson, MD, co-chair of the conference and Peter MacCallum Cancer Center in Australia, introduced the theme and Important issues of the 2023 WCLC in the interview by Oncology Frontier.

🔗Read more:

Editor's note: The annual international event in the field of lung cancer - the World Conference on Lung Cancer (WCLC) was held on Septemb...

08/10/2023

At this 2023 WCLC, We were very glad to interview Dr. Justin Gainor, from the Massachusetts General Hospital.

He shared with us his views on the Oral Presentation Session 9 (OA09) was topic as "Immunotherapy for Advanced NSCLC".

🔗Read more:

Editor's note: The third day of WCLC's Oral Presentation Session 9 (OA09) was topic as "Immunotherapy for Advanced NSCLC", which presented...

Cím

Budapest
1136

Weboldal

http://ioncol.com/

Értesítések

Ha szeretnél elsőként tudomást szerezni Oncology Frontier News új bejegyzéseiről és akcióiról, kérjük, engedélyezd, hogy e-mailen keresztül értesítsünk. E-mail címed máshol nem kerül felhasználásra, valamint bármikor leiratkozhatsz levelezési listánkról.

Parancsikonok

Megosztás

Kategória

Média- és hírszolgáltató